Date: 2016-09-15
Type of
information: Presentation of results at a congress
phase:
Announcement: presentation of results at the American Society for Preventative Cardiology (ASPC) 2016 Congress
Company: Akcea Therapeutics (USA - CA), a subsidiary of Ionis Pharmaceuticals (USA - CA)
Product:
Action
mechanism:
Disease: familial chylomicronemia syndrome
Therapeutic
area: Rare diseases - Genetic diseases
Country:
Trial
details:
Latest
news:
- • On September 15, 2016, Akcea Therapeutics, a wholly-owned subsidiary of Ionis Pharmaceuticals, focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders, announced that the company will present new data on the clinical characteristics, impact on quality of life and psychosocial consequences of living with familial chylomicronemia syndrome (FCS). The findings will be presented in two poster presentations at the American Society for Preventative Cardiology (ASPC) 2016 Congress being held September 16-18 in Boca Raton, Florida . These new data reflect findings from the largest study in patients with FCS conducted to date and provide new insights on the disease burden from the perspective of patients and caregivers.
- One poster titled "Characterizing Familial Chylomicronemia Syndrome: Baseline Data of the APPROACH Study" presents data from patients participating in APPROACH, the pivotal Phase 3 study evaluating the efficacy and safety of volanesorsen for the treatment of patients with FCS. The findings from this poster provide insights on the diversity of the overall patient population and the clinical characteristics of the disease.
- A second poster titled "The Clinical and Psychosocial Burden of Patients with Familial Chylomicronemia Syndrome" presents findings from a facilitator-moderated session, which details the impact of FCS on multiple quality of life measures for patients and caregivers.
- As part of its efforts to better capture the burden of illness experienced by FCS patients, Akcea recently launched the IN-FOCUS study at www.fcsinfocus.com. Information gathered from IN-FOCUS can help raise awareness about this rare, severe disease, lead to a better understanding of the burden of this disease and inform treatment approaches for patients with FCS.
Is
general: Yes
